Virtual Library
Start Your Search
J. Zwanziger
Author of
-
+
P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.01-060 - Prognostic Value of Serum Proteomic Test and of Comorbidity Index in Diversified Population with Lung Cancer (ID 1597)
09:30 - 09:30 | Author(s): J. Zwanziger
- Abstract
Background:
Proteomic (VeriStrat®) serum test has prognostic and predictive value in response to erlotinib; but the relation between comorbidity index and test performance and usefulness of this test in different races has not been adequately studied yet.
Methods:
Patients and Methods: We have reviewed electronic records of lung cancer patients from 09/2009 till 07/2014who had proteomic test performed to help with therapy choice. Extracted data was analyzed for survival using SAS software 9.4.
Results:
Among 49 qualified patients, 31 had VeriStrat® test done before and 18 after the first line treatment for metastatic disease. Nineteen cases with good VeriStrat® (VSG) test received erlotinib, and 12 received chemotherapy; 4 cases with VeriStrat® poor (VSP) results received erlotinib and 12 received chemotherapy. When stratified for test results “VSG vs. VSP” overall survival did not differ between white race and other races (HR=1.005; 95%CI=0.43-2.35; p=0.99). There was a trend of better survival for combined effect of VeriStrat® good test (VSG) and African American (AA) race. Patients with VSG test had better survival than patients with VSP test in each Charlson comorbidity index (CCI) stratum.
Conclusion:
Our study shows that there is no significant impact of race on prognostic and predictive values of VeriStrat® test. Prognostic value of this test is independent of comorbidities and older age.
